Rossari Biotech Limited announced its financial results for the quarter and nine months ended December 31, 2025.

For the third quarter of fiscal year 2026 (Q3 FY26), consolidated revenue from operations grew by 13% year-on-year to ₹581.7 crore, compared to ₹512.7 crore in Q3 FY25. EBITDA improved by 6% to ₹68.9 crore from ₹64.8 crore, although the EBITDA margin decreased to 11.8% from 12.6%. Profit After Tax (PAT) saw a 3% increase to ₹32.8 crore from ₹31.7 crore, with diluted Earnings Per Share (EPS) at ₹5.9*.

For the first nine months of fiscal year 2026 (9M FY26), consolidated revenue from operations stood at ₹1,711.5 crore, a 14% increase from ₹1,500.7 crore in the same period last year. EBITDA rose by 7% to ₹208.7 crore from ₹195.6 crore, with EBITDA margins at 12.2% compared to 13.0%. PAT increased by 1% to ₹103.2 crore from ₹101.9 crore, and diluted EPS was ₹18.6*.

Management noted healthy year-on-year growth in Q3 FY26 despite a softer domestic demand environment, supported by balanced contributions across business segments and international operations. The Home, Personal Care and Performance Chemicals (HPPC) segment grew 11% YoY, Textile Specialty Chemicals (TSC) grew 18% YoY, and Animal Health and Nutrition (AHN) grew 39% YoY. Profitability was impacted by ongoing investments in capacity expansion, product development, and market-seeding initiatives, which are expected to strengthen long-term competitive positioning.

A significant development is the Board's in-principle approval to set up greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia (KSA) through its wholly-owned subsidiary, Rossari International Limited. This move aims to enhance supply chain resilience and accelerate speed-to-market. The project's progress will be subject to customary evaluations and necessary regulatory approvals, and funding options are being evaluated.